ClinicalTrials.gg
RecruitingNCT07385235Updated Feb 11, 2026

Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'

A Phase 1 interventional study of AD-115A, AD-1151 in Gastric Ulcer, sponsored by Addpharma Inc.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Stomach Ulcer with a site in Korea, Republic of — 2 open to participants now, 2 under way, 1 of them phase 3. Stomach Ulcer · Korea, Republic of.

Planned enrollment
11th of 17
46 · median 199
Started
2026
with 1 other
Phase 1
7 of 20
1 open now
Registered
19th of 20
by date
Lead sponsor
2 of 20
Addpharma Inc.

Among the 20 studies in Stomach Ulcer with a site in Korea, Republic of, this one is the 11th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 in phase 1, and was the 19th registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

2 of the 20 studies in Stomach Ulcer with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Stomach Ulcer with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.

Read the detailed description

A randomized, open-label, single-dose, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of AD-115A and the administration of AD-1151 for healthy subjects in fasting state

03

Conditions studied

  • Gastric Ulcer

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
  • (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit

Exclusion criteria

Exclusion Criteria:

  • Individuals who have taken drugs that induce (e.g., barbiturates) or inhibit drug-metabolizing enzymes within 30 days prior to the start of the study (first dosing day), or have taken drugs that may affect this study within 10 days prior to the start of the study (first dosing day)
  • Other exclusions applied
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Sequence A

    Period 1 : Reference Drug(Rebanex Tab), Period 2 : Test Drug(Revaprazan sulfate) Single-dose oral administration of AD-115A (200 mg tablet) in Period 1, followed by single-dose oral administration of AD-1151 (200 mg tablet) in Period 2.

    Drug: AD-115A, AD-1151

  • Experimental
    Sequence B

    Period 1 : Test Drug(Revaprazan sulfate), Period 2 : Reference Drug(Rebanex Tab) Single-dose oral administration of AD-115A (200 mg tablet) in Period 1, followed by single-dose oral administration of AD-1151 (200 mg tablet) in Period 2.

    Drug: AD-115A, AD-1151

Interventions

  • DrugAD-115A, AD-1151

    Single-dose oral administration of AD-115A or AD-1151 (200 mg tablet), according to randomized sequence.

06

What researchers measure

Primary outcomes

  1. Maximum concentration of drug in plasma (Cmax)

    Cmax of AD-115A

    Time frame: pre-dose to 24 hours

  2. Area under the plasma concentration-time curve during dosing interval (AUCt)

    AUCt of AD-115A

    Time frame: pre-dose to 24 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Mar 2026, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 4, 2026
StartActual
Jan 27, 2026
Primary completionEst.
Mar 7, 2026
CompletionEst.
Mar 16, 2026
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07385235
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Jan 27, 2026
Primary completion
Mar 7, 2026 (estimated)
Completion
Mar 16, 2026 (estimated)
Last update
Feb 11, 2026

Study contacts

JaeHun Jung
Contact
jhjung@addpharma.co.kr
+82-31-891-5683

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion